In brief: Takeda gains US approval for £46m Shire acquisition

Shire completes $2.4bn sale of oncology business
Credit: Shutterstock.com/ pichetw

Japan’s Takeda Pharmaceutical has gained the approval of US regulators for its £46 billion acquisition of Irish pharma giant, Shire.

According to a company press release, Takeda has received unconditional clearance from the US Federal Trade Commission as it moves closer to becoming a major player in the pharma sector.

The company is now waiting for regulatory approval in China, the EU and elsewhere, as well as from shareholders of both companies.

The deal, announced in May, is expected to close in the first half of 2019.